欧盟批准犬利什曼病疫苗有效性的系统综述与Meta分析
本研究通过系统综述与Meta分析评估欧盟批准犬用利什曼病疫苗对L. infantum感染的保护效果,纳入10项研究共1394只犬。总体分析显示疫苗接种显著降低感染风险(RR 0.40,95%CI 0.23-0.72),CaniLeish®疫苗显著有效(RR 0.38,95%CI 0.20-0.72),而Letifend®未达统计学显著(RR 0.43,95%CI 0.15-1.22)。
要点
- 总体疫苗对犬L. infantum感染有显著保护作用(RR 0.40)。
- CaniLeish®显著降低感染风险,NNT为3.77。
- Letifend®效果未达统计学显著,NNT为10.99。
核心结论
- 疫苗接种能显著预防犬L. infantum感染,但CaniLeish®与Letifend®有效性可能不同,需进一步研究确认。
研究设计与样本
- 系统综述与 pairwise Meta分析,遵循PRISMA-P,纳入10项研究共1394只犬。
主要发现
- 总体分析显示疫苗显著降低感染风险(RR 0.40,95%CI 0.23-0.72;I2 70%;P<0.01)。
- CaniLeish®显著有效(RR 0.38,95%CI 0.20-0.72;I2 0%;P<0.05)。
- Letifend®效果未达显著(RR 0.43,95%CI 0.15-1.22;I2 37%)。
- CaniLeish®的NNT为3.77(95%CI 2.59-6.94),Letifend®的NNT为10.99(95%CI 8.28-16.34)。
关键数值与推荐
- CaniLeish®:RR 0.38(95%CI 0.20-0.72),NNT 3.77(95%CI 2.59-6.94)。
- Letifend®:RR 0.43(95%CI 0.15-1.22),NNT 10.99(95%CI 8.28-16.34)。
临床怎么用
- 在欧盟流行区,可优先考虑使用CaniLeish®以降低犬L. infantum感染风险。
- Letifend®的实际保护效果需更多研究验证,使用时应结合风险评估。
局限性
- 纳入研究间存在异质性(总体I2 70%),可能影响结果稳定性。
- 仅纳入10项研究,且部分疫苗证据有限,需进一步头对头比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Leishmania (L.) infantum is a vector-borne parasite currently endemic in several Southern countries of European Union (EU), and dogs represent the main reservoir and hosts. Data from clinical trials are inconsistent with respect to the efficacy of vaccination against L. infantum infection. Therefore, a quantitative synthesis via pairwise meta-analysis was performed in agreement with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) to increase the strength of evidence and assess the real efficacy profile of vaccines against L. infantum currently approved in EU. Data obtained from 1,394 dogs were extracted from 10 studies. The overall analysis indicated that vaccination is significantly effective in protecting against L. infantum infection (RR 0.40, 95%CI 0.23-0.72; I2 70%; P < 0.01 vs. negative controls). The subset analysis performed by excluding the effect modifiers and by considering only the studies that assessed the efficacy of vaccines currently available in EU, indicated that CaniLeish® (RR 0.38, 95%CI 0.20-0.72; I2 0%), but not Letifend® (RR 0.43, 95%CI 0.15-1.22; I2 37%), significantly protected against L. infantum infection when compared to negative controls (P < 0.05). The number needed to treat analysis showed that 3.77 (95%CI 2.59-6.94) and 10.99 (95%CI 8.28-16.34) dogs had to be treated with CaniLeish® and Letifend®, respectively, to prevent one case of infection compared to negative controls. Vaccination is effective in protecting against the risk L. infantum infection, but further studies are needed to assess whether CaniLeish® and Letifend® are characterized by similar efficacy profile.
引用
- Calzetta L, Pistocchini E, Ritondo BL, et al. Immunoprophylaxis pharmacotherapy against canine leishmaniosis: A systematic review and meta-analysis on the efficacy of vaccines approved in European Union. Vaccine. 2020. PMID: 32883556. doi:10.1016/j.vaccine.2020.08.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。